Cellectar Biosciences and SpectronRx, a radiopharmaceutical contract developer and manufacturer, have signed a commercial supply agreement for the manufacture of Cellectar’s first-in-class cancer therapy, iopofosine I 131, the company announced today.

“This partnership is part of our multi-sourced global supply strategy, which is key for Cellectar’s commercialization plans for iopofosine I 131,” Cellectar President and CEO James Caruso said in a statement. “SpectronRx’s expertise and strategically located facilities offer significant logistical benefits for global market distribution while expanding our manufacturing capabilities for iopofosine I 131.”

According to a release, SpectronRx will use its facilities in Indiana and Belgium to produce iopofosine I 131.

As previously reported, the Food and Drug Administration granted I-131 Orphan Drug and Fast Track Designations for various cancer indications.